Roivant Alliance Takes SK Into Cancer, Intractable Diseases

Invests $200m In TPD Platform

 
• By Jung Won Shin
SK and Roivant's partnership
SK First Korean Firm To Enter US Targeted Protein Degradation Market • Source: SK Holdings

More from South Korea

More from Focus On Asia